Purpose: To describe the feasibility of balloon angioplasty using a long balloon for chronic femoropopliteal occlusions by evaluating angiographic dissection patterns for optimization of outcomes in balloon angioplasty. Methods: A retrospective, single-center analysis examined 101 symptomatic patients (mean age 75.6±9.9 years; 65 men) with single de novo femoropopliteal occlusive lesions treated with balloon angioplasty between August 2012 and October 2016. The patients were classified into 2 groups for comparison of angiographic dissection patterns: 51 patients were treated with balloon angioplasty using long balloons (L-BA; defined as ≥220 mm in length) and 50 patients were treated with short balloon angioplasty (S-BA; defined as <150-mm-long balloons). Results: Severe vessel dissection patterns, defined as type C or higher, were fewer in the L-BA group (47.1% vs 70.0% in the S-BA group, p=0.019) and the total dissection length was shorter (92.7±72.6 vs 160.4±84.6 mm in the S-BA group, p<0.001). Although the results showed no significant differences between the two groups regarding the length of chronic total occlusions (L-BA: 228.6±73.2 vs S-BA: 226.0±53.8 mm, p=0.83), inflation pressure (L-BA; 8.2±2.6 vs S-BA: 8.1±2.9 atm, p=0.86), and the other lesion characteristics, inflation time was significantly longer in the L-BA group (161.2±68.7 seconds vs 51.1±54.0 seconds in the S-BA group, p<0.001). Multivariate analysis identified a balloon length ≥220 mm as an independent negative predictor of severe vessel dissection (odds ratio 0.29, 95% confidence interval 0.11 to 0.83, p=0.02). Conclusion: Using long balloons for balloon angioplasty may help prevent severe vessel dissection in chronic femoropopliteal occlusions.
SchmidtABausbackYPiorkowskiMet al. Retrograde recanalization technique for use after failed antegrade angioplasty in chronic femoral artery occlusions. J Endovasc Ther. 2012;19:23–29.
2.
TanMUrasawaKKoshidaRet al. Anterolateral popliteal puncture technique: a novel retrograde approach for chronic femoropopliteal occlusions. J Endovasc Ther. 2017;24:525–530.
3.
KitrouPParthipunADiamantopoulosAet al. Targeted true lumen re-entry with the Outback catheter: accuracy, success, and complications in 100 peripheral chronic total occlusions and systematic review of the literature. J Endovasc Ther. 2015;22:538–545.
4.
ArmstrongEJSaeedHAlvandiBet al. Nitinol self-expanding stents vs balloon angioplasty for very long femoropopliteal lesions. J Endovasc Ther. 2014;21:34–43.
5.
NorgrenLHiattWRDormandyJAet al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1–S75.
6.
SogaYIidaOHiranoKet al. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent. J Vasc Surg. 2010;52:608–615.
7.
SchmidtAPiorkowskiMGörnerHet al. Drug-coated balloons for complex femoropopliteal lesions: 2-year results of a real-world registry. JACC Cardiovasc Interv. 2016;9:715–724.
8.
MicariAVadalàGCastriotaFet al. 1-Year results of paclitaxel-coated balloons for long femoropopliteal artery disease: evidence from the SFA-Long Study. JACC Cardiovasc Interv. 2016;9:950–956.
9.
FujiharaMTakaharaMSasakiSet al. Angiographic dissection patterns and patency outcomes after balloon angioplasty for superficial femoral artery disease. J Endovasc Ther. 2017;24:367–375.
DotterCTJudkinsMP. Transluminal treatment of arteriosclerotic obstruction. description of a new technic and a preliminary report of its application. Circulation. 1964;30:654–670.
12.
van der LugtAGussenhovenEJMaliWPet al. Effect of balloon angioplasty in femoropopliteal arteries assessed by intravascular ultrasound. Eur J Vasc Endovasc Surg. 1997;13:549–556.
13.
BosiersMDelooseKCallaertJet al. Results of the Protégé EverFlex 200-mm-long nitinol stent (ev3) in TASC C and D femoropopliteal lesions. J Vasc Surg. 2011;54:1042–1050.
14.
TepeGLairdJSchneiderPet al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495–502.
15.
SherisSJCanosMRWeissmanNJ. Natural history of intravascular ultrasound-detected edge dissections from coronary stent deployment. Am Heart J. 2000;139:59–63.
16.
LiuXTsujitaKMaeharaAet al. Intravascular ultrasound assessment of the incidence and predictors of edge dissections after drug-eluting stent implantation. JACC Cardiovasc Interv. 2009;2:997–1004.
17.
ChamiéDBezerraHGAttizzaniGFet al. Incidence, predictors, morphological characteristics, and clinical outcomes of stent edge dissections detected by optical coherence tomography. JACC Cardiovasc Interv. 2013;6:800–813.
18.
McKinseyJFZellerTRocha-SinghKJet al. Lower extremity revascularization using directional atherectomy: 12-month prospective results of the DEFINITIVE LE study. JACC Cardiovasc Interv. 2014;7:923–933.
19.
TepeGBeschornerURuetherCet al. Drug-eluting balloon therapy for femoropopliteal occlusive disease: predictors of outcome with a special emphasis on calcium. J Endovasc Ther. 2015;22:727–733.
20.
ShammasNWLamRMustaphaJet al. Comparison of orbital atherectomy plus balloon angioplasty vs. balloon angioplasty alone in patients with critical limb ischemia: results of the CALCIUM 360 randomized pilot trial. J Endovasc Ther. 2012;19:480–488.
